Leukemia therapy Medicare rates
HHS would create a separate Medicare hospital diagnosis- related group (DRG 492) for chemotherapy patients with acute leukemia to reflect their more costly care versus nonleukemia cancer patients, under proposed changes to the DRG system published in the June 3 Federal Register. DRG 492's price would be about five times more than DRG 410 under the proposal. The DRG revisions were advocated by Cetus with support from Health Technology Associates and Fox, Bennett and Turner. HTA found that the median treatment cost for DRG 410 patients is $ 3,203, while patients with leukemias or testicular cancer cost $ 6,000 or more, and those with acute nonlymphocytic leukemia cost $ 14,488.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth